iBio, Inc. Intellectual Property Update
September 20 2017 - 8:00AM
iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based
biotechnology for developing and manufacturing biological products,
provided an update on recent patents and inventions.
On September 19, 2017, iBio received US patent
serial number 9,765,349 entitled “SYSTEM FOR EXPRESSION OF GENES IN
PLANTS” from the U.S. Patent and Trademark Office. This is in
addition to US 9,551,001 issued earlier in 2017. These
patents join previously issued US patents, 7,491,509, 7,683,238,
7,692,063, 8,058,511, 8,597,942 and 8,951,791 that protect
intellectual property owned by iBio.
Further protection of iBio’s intellectual
property in the fibrosis field was also obtained from an additional
patent covering iBio’s idiopathic pulmonary fibrosis (IPF) and
systemic sclerosis product pipeline. This patent on an
invention by Dr. Carol Feghali-Bostwick and colleagues, US
9,556,252 entitled "USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF
FIBROSIS," was issued on January 31,2017 and included claims
covering composition of matter and methods of use for
endostatin-related peptides. Previously issued members of
this patent family include US patents 9,365,616, 8,507,441 and
8,716,232.
iBio obtained exclusive licenses to the prior
patents and related intellectual property developed by Dr.
Feghali-Bostwick and then entered into an ongoing collaboration
agreement with Dr. Feghali-Bostwick's current institution, the
Medical University of South Carolina (MUSC), which led to further
development and invention of the potentially breakthrough
biotherapeutic approach to fibrotic diseases described by this
family of patents. Additional patent applications on recent
inventions by iBio and its collaborators in this field are pending
in the U.S. and internationally.
In the antibody and vaccine categories, iBio
received a Notice of Allowance for US serial number 14/336,071
entitled “INFLUENZA HEMAGGLUTININ ANTIBODIES, COMPOSITIONS AND
RELATED METHODS” that will join issued family member US
8,784,819. In its international portfolio iBio received a
Notice of Allowance for Canadian application 2642054 entitled
“INFLUENZA ANTIGEN, VACCINE COMPOSITIONS, AND RELATED METHODS”.
iBio is actively pursuing further development of
new inventions in both the product and technology categories at its
iBio CDMO laboratories in Texas and also in collaboration with high
quality collaborators. The Company intends to pursue appropriate
U.S. and international patent protection for these inventions and
will also maintain trade secret protection for certain innovations
it prefers to keep confidential.
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO, LLC. in Bryan, Texas. The facility
houses laboratory and pilot-scale operations, as well as
large-scale automated hydroponic systems capable of growing over
four million plants as "in process inventory" and delivering over
300 kilograms of therapeutic protein pharmaceutical active
ingredient per year. iBio applies its technology for the benefit of
its clients and the advancement of its own product interests. The
Company’s pipeline is comprised of proprietary candidates for the
treatment of a range of fibrotic diseases including idiopathic
pulmonary fibrosis, systemic sclerosis, and scleroderma.
IBIO-CFB03, based on the Company's proprietary gene expression
technology, is the Company’s lead therapeutic candidate being
advanced for IND development.
Further information is available at:
www.ibioinc.com
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
ICR, Inc. (Investor and Media Inquiries):
Stephanie CarringtonTel. +1
646-277-1282Stephanie.Carrington@icrinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024